Fig. 2

The association between MRCCAT1 and clinicopathological characteristics of ccRCC patients. a qRT-PCR analysis of MRCCAT1 between Fuhrman III-IV grade and Fuhrman I-II grade ccRCC samples. P < 0.01 by Mann-Whitney U test. b qRT-PCR analysis of MRCCAT1 between tumor >7 cm and tumor ≤7 cm ccRCC samples. P < 0.01 by Mann-Whitney U test. c Patients in the MRCCAT1 high expression group (n = 34) had shorter recurrence free survival time than those in the MRCCAT1 low expression group (n = 34). P = 0.0034 by Log-rank test. d Patients in the MRCCAT1 high expression group (n = 34) had shorter overall survival time than those in the MRCCAT1 low expression group (n = 34). P = 0.0092 by Log-rank test. e The 5′-RACE and 3′-RACE assays were performed to determine the transcriptional initiation and termination sites of MRCCAT1. Left, representative images of PCR products from the 5′-RACE and 3′-RACE procedure. Right, sequence of the second-round PCR products revealed the boundary between the universal anchor primer and the MRCCAT1 sequences. f Schematic annotation of MRCCAT1 genomic locus on chromosome 5: 95,900,228-95,901,132 and composed of 2 exons in humans. Blue rectangles represent exons